News item

Alveron Pharma BV raises a further EUR 3.9 million to progress first in class drug

Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111, a first-in-class drug to treat anticoagulant related bleeds. Investors Thuja Capital, Waterman Ventures and Oost NL participated in the fund raising alongside a loan from Rijksdienst Voor Ondernemend Nederland (RVO). The round follows seed financing of EUR 6.5 million in 2019.

The additional funding will finance the OKL-1111 program including a first in man study which is anticipated to start in Q3 2022.

Alveron’s drug is unique as it reverses the effects of all the major anticoagulants (including all DOACs and vitamin K antagonists) and platelet aggregation inhibitors like clopidogrel. This enables clinicians to intervene in emergencies without prior knowledge of the type of anticoagulant used and potentially simplifies treatment protocols. The drug, in contrast to leading competitors, is not a biologic nor a blood derived material, providing both cost and safety advantages.

Alveron’s CEO, Dr Ben Nichols, commented “anticoagulant-related bleeding is a significant issue and poorly served by either selective reversal agents or off label use of blood derived products; with 2-3% of all anti-coagulated patients suffering bleeding events, some of which are life threatening, this is an area that needs better therapies”.

Share this news

Share on facebook
Share on twitter
Share on linkedin

Fighting malaria is fighting poverty

Diseases that spread across the globe come and go, but malaria has been around for thousands of years. The number of people affected by the disease is on the rise and it hits lower-income countries the hardest. So how can we fight malaria, and what will it bring to the world if we manage to do so? Koen Dechering, CEO of TropIQ Health Sciences, explains why more needs to be done and how his company contributes to eradicating the disease once and for all.

Read More »

Subscribe the NTC Newsletter

We care about your privacy: Read more

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!